Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910114 · ClinicalTrials.gov registry record
Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 500
- Enrollment target
NCT03910114: Completed study, sponsored by Vanderbilt University Medical Center.
NCT03910114 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03910114 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU Primary Objectives: Review functional analysis curves and data of fMRU studies and determine enhancement characteristics in the kidneys of the three GBCAs (Dotarem, Gadovist, Magnevist)
Primary Outcome
The enhancement curves will provide peak enhancement values within the aorta and kidneys (Time to peak = TTP) and allow comparison between the GBCAs.
Interventions
- DRUG Dotarem
- DRUG Magnevist
- DRUG Gadovist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 1990-07-01 |
| Est. Completion | 2019-04-01 |
What the finished NCT03910114 record still lists
NCT03910114 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Dotarem is the first listed.
NCT03910114 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03910114 about?
NCT03910114 is a clinical study titled "Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography". Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU Primary Objectives: Review functional analysis curves and data of fMRU studies and determine enha...
What is the current status of trial NCT03910114?
This trial is currently completed. The enrollment target is 500 participants. The study started on 1990-07-01. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03910114?
The interventions under investigation include: Dotarem (DRUG), Magnevist (DRUG), Gadovist (DRUG).
Who is sponsoring clinical trial NCT03910114?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI